The negative TTM P/E renders the traditional earnings multiple unusable, while the 22.41x EV/EBITDA sits below Amicus at 114.88x yet above peers with no meaningful EBITDA, so the comparison suggests ANAB is priced somewhere between a royalty vehicle and a clinical-stage risk asset. The 38.45x P/B is almost certainly an artifact of near-zero book equity — equity bottomed at negative $44.7M in 2025Q2 — and investors may be better served treating the $238M cash balance and GSK royalty stream as the valuation floor, with the internal pipeline valued as a call option rather than through headline multiples.

The TTM operating margin of 20.42% appears to be propped by a single quarter (2026Q2, operating margin 2.4% but operating income positive on just $27.5M revenue after R&D collapsed to $2.7M from $33.9M), so it likely understates the normalized cash cost of the clinical engine rather than reflecting durable operating leverage. The -5.64% net margin despite positive operating results implies below-the-line items — including non-operating gains that pushed 2026Q2 net income to $183.9M against $67M operating income — dominate the bottom line, so true earning power is not yet evidenced and royalty income excluding one-time milestones remains the only defensible core-margin measure.

Total assets have fallen 35.8% from $493.4M in 2024Q3 to $317.0M in 2026Q2, so any positive ROIC print is partly mechanical — denominator shrinkage — and is amplified by the 2026Q2 R&D cliff that temporarily reduced expensed investment. With equity at just $10.6M against $269.6M of debt, the ROE figure is mathematically unstable and arguably meaningless; investors should treat the negative TTM ROE as indicative that, to date, capital deployed into the pipeline has not generated commensurate economic returns versus peers like Kymera-type platform names still in investment phase.

The extreme DPO prints — 840 days in 2026Q1 versus -3 days in 2025Q4 — appear to reflect one-time payables or accrual reversals rather than a stable supplier-credit strategy, and the cash conversion cycle cannot be computed due to unavailable DIO data, so a full working-capital efficiency read is not possible. Combined with near-zero capex (0.1–0.6% of revenue per cash flow statements), the ultra-low asset turnover confirms this is a capital-light licensing model where efficiency should be judged on cash conversion, which has instead shown operating cash flow negative in most quarters.

With debt-to-assets at 85.0% and equity at only $10.6M after a trough of negative $44.7M, the capital structure appears fragile to any interruption in milestone or royalty inflows — the 2026Q1 interest coverage print of -1.53x versus 3.52x in 2025Q4 underscores how coverage swings with lumpy revenue. The historical combination of $69M in buybacks executed during the same window debt ballooned suggests capital allocation and financing decisions warrant monitoring for refinancing or covenant risk, though no specific covenant terms are disclosed in the supplied data.